Edwards Lifesciences Corporation $EW Shares Sold by Prime Capital Investment Advisors LLC

Prime Capital Investment Advisors LLC lessened its stake in Edwards Lifesciences Corporation (NYSE:EW) by 28.2% during the second quarter, Holdings Channel reports. The firm owned 2,871 shares of the medical research company’s stock after selling 1,127 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Edwards Lifesciences were worth $225,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in EW. Nuveen LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $330,881,000. Jennison Associates LLC boosted its holdings in shares of Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock valued at $731,036,000 after purchasing an additional 2,576,383 shares during the last quarter. Woodline Partners LP lifted its holdings in shares of Edwards Lifesciences by 7,805.0% during the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after acquiring an additional 814,917 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Edwards Lifesciences by 339.7% during the 1st quarter. AQR Capital Management LLC now owns 918,537 shares of the medical research company’s stock valued at $65,381,000 after acquiring an additional 709,648 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Edwards Lifesciences by 37.0% during the 1st quarter. BNP Paribas Financial Markets now owns 1,946,818 shares of the medical research company’s stock valued at $141,105,000 after acquiring an additional 525,822 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Canaccord Genuity Group lifted their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a report on Friday, July 25th. Truist Financial lifted their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a report on Friday, July 25th. Wells Fargo & Company lifted their target price on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a report on Thursday, August 7th. Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Thursday, July 10th. Finally, William Blair upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $87.06.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $74.02 on Monday. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a P/E/G ratio of 3.55 and a beta of 1.05. The company’s fifty day moving average price is $78.09 and its two-hundred day moving average price is $76.17.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. The company had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.